RESUMO
Objective To discuss relative risk factors and prognosis factors of chronic obstructive pulmonary disease (COPD) combined with respiratory failure.Methods Retrospective investigation was carried out to analyze the clinical data of 110 patients with COPD from March 2005 to February 2008.These patients were divided into two groups according to the condition of respiratory failure,respiratory failure group(40 cases) and non-respiratory failure group(70 cases).Results There were significant differences in the frequency of exacerbation,uric acid,total protein,albumin,bady-mass index between two groups [(5.54 ± 1.16) times/year vs (2.75 ±0.78) times/year,(283.75 ±72.49) mmol/L vs (359.87 ±41.50)mmol/L,(58.77 ± 1.54) g/Lvs(63.95 ±2.04) g/L,(36.15 ± 1.08) g/L vs(36.96 ± 1.48) g/L,(20.33 ±0.99)kg/m2 vs (21.16 ± 1.36) kg/m2](P < 0.01).There were significant differences in COPD stage,nosocomial infection,acid-base disturbance between two groups(P< 0.05 or < 0.01).There was no statistical significance of partial pressure of oxygen in artery between the respiratory failure survival patients and dead patients (P >0.05).There were statistical significances in pH,partial pressure of carbon dioxide in artery,blood Na+,blood Cl-between the respiratory failure survival patients and dead patients (P< 0.01).Conclusion There are many relative risk factors of COPD combined with respiratory failure.
RESUMO
OBJECTIVE:To evaluate the therapeutic efficacy of oxygen-driven aerosol inhalation of Ventolin plus Atrovent and Budesonide suspension for acute episode of intermediate or severe degree of bronchial asthma. METHODS:A total of 48 patients with bronchial asthma were divided into two groups randomly:26 cases in the treatment group received normal saline (1 mL) +Ventolin (2 mL) + Atrovent (2 mL) and Budesonide suspension(4 mL) q6 h in addition to the routinetherapy by high-flow oxygen driven in addition to the routine therapy; 22 cases in the control group received Ventolin inhaler(200 ?g) q 6 h. The improvement of clinical symptoms in the two groups after treatment for 3 days,the forced expiratory volume in one second (FEV1),forced vital capacity (FVC),peak expiratory flow (PEF) at 3 h and 5 days,respectively,the blood sugar level,arterial blood gas index as well as duration of systemic use of hormone and the hospital days were compared between two groups. RESULTS:After treatment for 3 days,the effective rate in the treatment group(24/26) was significantly higher than in the control group (14/22),showing significant differences between two groups. At 3 h,there were significant differences between the treatment group and the control group in FEV1 and PEF but not in FVC; at 5 days,there were significant differences between the treatment group and the control group in FEV1,FVC and PEF. On day 5,there were significant differences between two groups in PaO2,PaCO2 and blood sugar level as well as in the duration of systemic use of hormone and the hospital days. CONCLUSION:Aerosol inhalation of Ventolin plus Atrovent and Budesonide suspension shows remarkable therapeutic efficacy for acute episode of intermediate or severe degree of bronchial asthma.
